Related Experiment Videos
[Antithrombotic therapy in atrial fibrillation]
1Unidad de Arritmias, Servicio de Cardiología, Fundación Jiménez Díaz, Madrid.
Revista Espanola De Cardiologia
|January 1, 1996
Summary
Oral anticoagulation is recommended for patients with rheumatic mitral valve disease and atrial fibrillation to prevent embolic events. Adjustments in dosage or additional antiplatelet therapy may be needed for recurrent embolism or specific patient profiles.
Area of Science:
- Cardiology
- Thrombosis Management
Context:
- Atrial fibrillation (AF) poses a significant embolic risk, particularly in patients with rheumatic mitral valve disease (MVD).
- Managing anticoagulation in AF requires careful consideration of patient-specific risk factors and underlying conditions.
Purpose:
- To outline evidence-based recommendations for antithrombotic therapy in patients with atrial fibrillation.
- To guide the management of anticoagulation intensity and adjunctive therapies to minimize embolic events.
Summary:
- Oral anticoagulation with a target INR of 2.0-3.0 is mandatory for rheumatic MVD patients with AF.
- For recurrent embolism, increase INR to 2.5-3.5 or add dipyridamole/aspirin. Cardioversion requires 3-4 weeks of anticoagulation pre- and post-procedure.
- Lone AF in patients <60 years has low embolic risk; aspirin may suffice for those >60 with low risk factors. High-risk patients benefit from oral anticoagulation.
Impact:
- Provides clear guidelines for optimizing anticoagulation strategies in diverse AF patient populations.
- Aims to reduce the incidence of stroke and systemic embolism in patients with atrial fibrillation.
- Highlights the need for further research into the efficacy of other antithrombotic agents in AF.